Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis

doi:10.4239/wjd.v16.i4.101731

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-1)

Sum=0

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=0

Apr 15, 2025 (publication date) through Feb 28, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Diabetes. Apr 15, 2025; 16(4): 101731
Published online Apr 15, 2025. doi: 10.4239/wjd.v16.i4.101731

Full Size Figure Download Figure

Figure 3 Forest plot highlighting the proportion of study subjects with permanent discontinuation of the study drug in the tirzepatide vs insulin groups.

Citation: Kamrul-Hasan ABM, Pappachan JM, Dutta D, Nagendra L, Kuchay MS, Kapoor N. Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis. World J Diabetes 2025; 16(4): 101731
URL: https://www.wjgnet.com/1948-9358/full/v16/i4/101731.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i4.101731